OBJECTIVE: To evaluate the association between biomarkers of inflammation and endothelial dysfunction and Framingham scores (FS) for risk of coronary heart disease (FS-CHD), stroke (FS-Stroke) or any cardiovascular event (FS-CVE) in HIV-infected on suppressive highly active antiretroviral therapy (HAART). METHODS: A cross-sectional study was conducted in 73 HIV-infected patients and 23 healthy controls. Inflammatory molecules and endothelial dysfunction markers were measured using a multiplex immunoassay (plasminogen activator inhibitor type 1 (PAI-1), soluble TNF receptor type 1 (sTNF-R1), soluble CD40 ligand (sCD40L), soluble E-selectin (sE-selectin), soluble P-selectin (sP-selectin), soluble intercellular adhesion molecules (sICAM-1) and soluble vascular cell adhesion molecule (sVCAM-1). Outcome variables were FS-CHD ≥10%, FS-Stroke ≥5% and FS-CVE ≥10%. RESULTS: Significant differences (p < 0.05) were found comparing controls and HIV patients for PAI-1 (5.4 vs. 13.5 ng/dL), sTNF-R1 (0.85 vs. 1.09 ng/dL), sICAM-1 (529 vs. 858 ng/dL), sE-selectin (73.7 vs. 120 ng/dL), sP-selectin (676 vs. 1511 ng/dL) sCD40L (76 vs. 307 ng/dL), FS-CHD (4% vs. 7.8% L), FS-Stroke (2% vs. 2.8%) and FS-CVE (5% vs. 11%). In HIV-infected patients, the adjusted logistic regression analysis revealed that sTNF-R1 levels were significantly associated with increased FS-CHD>10% (OR: 11.51 (95% CI: 1.14; 115.84); p = 0.038) and FS-CVE (OR: 12.41 (95% CI: 1.25; 123.23); p = 0.031). CONCLUSIONS: HIV-infected patients show higher levels of soluble inflammatory and endothelial dysfunction markers than controls and have a two-fold increased FS of presenting coronary heart disease, stroke or cardiovascular events at 10 years. Furthermore, sTNF-R1 displayed the best association with FS of coronary heart disease and any cardiovascular event in our patients.
OBJECTIVE: To evaluate the association between biomarkers of inflammation and endothelial dysfunction and Framingham scores (FS) for risk of coronary heart disease (FS-CHD), stroke (FS-Stroke) or any cardiovascular event (FS-CVE) in HIV-infected on suppressive highly active antiretroviral therapy (HAART). METHODS: A cross-sectional study was conducted in 73 HIV-infectedpatients and 23 healthy controls. Inflammatory molecules and endothelial dysfunction markers were measured using a multiplex immunoassay (plasminogen activator inhibitor type 1 (PAI-1), soluble TNF receptor type 1 (sTNF-R1), soluble CD40 ligand (sCD40L), soluble E-selectin (sE-selectin), soluble P-selectin (sP-selectin), soluble intercellular adhesion molecules (sICAM-1) and soluble vascular cell adhesion molecule (sVCAM-1). Outcome variables were FS-CHD ≥10%, FS-Stroke ≥5% and FS-CVE ≥10%. RESULTS: Significant differences (p < 0.05) were found comparing controls and HIV patients for PAI-1 (5.4 vs. 13.5 ng/dL), sTNF-R1 (0.85 vs. 1.09 ng/dL), sICAM-1 (529 vs. 858 ng/dL), sE-selectin (73.7 vs. 120 ng/dL), sP-selectin (676 vs. 1511 ng/dL) sCD40L (76 vs. 307 ng/dL), FS-CHD (4% vs. 7.8% L), FS-Stroke (2% vs. 2.8%) and FS-CVE (5% vs. 11%). In HIV-infectedpatients, the adjusted logistic regression analysis revealed that sTNF-R1 levels were significantly associated with increased FS-CHD>10% (OR: 11.51 (95% CI: 1.14; 115.84); p = 0.038) and FS-CVE (OR: 12.41 (95% CI: 1.25; 123.23); p = 0.031). CONCLUSIONS:HIV-infectedpatients show higher levels of soluble inflammatory and endothelial dysfunction markers than controls and have a two-fold increased FS of presenting coronary heart disease, stroke or cardiovascular events at 10 years. Furthermore, sTNF-R1 displayed the best association with FS of coronary heart disease and any cardiovascular event in our patients.
Authors: Alison Morris; Matthew R Gingo; M Patricia George; Lorrie Lucht; Cathy Kessinger; Vikas Singh; Maria Hillenbrand; Michelle Busch; Deborah McMahon; Karen A Norris; Hunter C Champion; Mark T Gladwin; Yingze Zhang; Chad Steele; Frank C Sciurba Journal: AIDS Date: 2012-03-27 Impact factor: 4.177
Authors: James D Wilkinson; Paige L Williams; Wendy Yu; Steven D Colan; Armando Mendez; Justin P V Zachariah; Russell B Van Dyke; William T Shearer; Renee E Margossian; Steven E Lipshultz Journal: AIDS Date: 2018-06-19 Impact factor: 4.177
Authors: Katherine Krauskopf; Mark L Van Natta; Ronald P Danis; Sapna Gangaputra; Lori Ackatz; Adrienne Addessi; Alex D Federman; Andrea D Branch; Curtis L Meinert; Douglas A Jabs Journal: J Int Assoc Provid AIDS Care Date: 2013 Sep-Oct
Authors: Alessandra D'Abramo; Claudia D'Agostino; Alessandra Oliva; Marco Iannetta; Gabriella D'Ettorre; Francesco Vullo; Massimo Mancone; Maria Rosa Ciardi; Claudio Maria Mastroianni; Vincenzo Vullo Journal: ISRN AIDS Date: 2013-12-05
Authors: Alessandra D'Abramo; Maria Antonella Zingaropoli; Alessandra Oliva; Claudia D'Agostino; Samir Al Moghazi; Giulia De Luca; Marco Iannetta; Gabriella d'Ettorre; Maria Rosa Ciardi; Claudio Maria Mastroianni; Vincenzo Vullo Journal: PLoS One Date: 2016-02-25 Impact factor: 3.240
Authors: Cecilia M Shikuma; Dominic C Chow; Louie Mar A Gangcuangco; Guangxiang Zhang; Sheila M Keating; Philip J Norris; Todd B Seto; Nisha Parikh; Kalpana J Kallianpur; Beau K Nakamoto; Lorna S Nagamine; Lishomwa C Ndhlovu; Jason D Barbour Journal: PLoS One Date: 2014-02-27 Impact factor: 3.240